Advertisement

Topics

Cortexyme, Inc. Company Profile

08:17 EST 16th December 2018 | BioPortfolio

Based in South San Francisco, California, Cortexyme is a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and other degenerative disorders. Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The company’s lead compound, COR388, is the subject of an ongoing phase 1 clinical trial; additional proprietary small molecules are moving forward in preclinical development. Cortexyme’s investors include Pfizer, Takeda Ventures, Lamond Family, Dolby Family Ventures, Breakout Ventures, and Breakout Labs. For more information on Cortexyme, visit www.cortexyme.com.


News Articles [3 Associated News Articles listed on BioPortfolio]

Allogene, Cortexyme & RDMD Headline Xconomy’s Dec. 5 Biotech Forum

Each new technology has a story behind it. On Dec. 5, our Xchange Forum will offer a behind-the-scenes look at how some of them aim to transform healthcare. Xconomy’s San Francisco Biotech: The Next...

Cortexyme Assembles World Class Clinical Advisory Board to Support Its Alzheimer’s Disease Clinical Development Program

Cortexyme, Inc., a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, announced the f...

Cortexyme Announces Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer’s Patients

-- Data on safety and exploratory cognitive testing presented in late-breaking poster at the 2018 Clinical Trials of Alzheimer’s Disease Conference -- Phase 2 en...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Cortexyme, Inc.

Based in South San Francisco, California, Cortexyme is a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and ...

More Information about "Cortexyme, Inc." on BioPortfolio

We have published hundreds of Cortexyme, Inc. news stories on BioPortfolio along with dozens of Cortexyme, Inc. Clinical Trials and PubMed Articles about Cortexyme, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cortexyme, Inc. Companies in our database. You can also find out about relevant Cortexyme, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record